Rinzimetostat efficacy wanes further as the company moves into phase 3.

J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.

The groups spend big on Terns and Arcellx.

Replimune gets a second chance, while Sarclisa could go subcutaneous.

The group wants to improve on its own Welireg in a new phase 3 trial.